

From: REDACTED

To: REDACTED lake/ppd/abbott;nsf: REDACTED @abbott.com;smtp

Cc: REDACTED lake/ppd/abbott@abbott; REDACTED ED  
 REDACTED /lake/ppd/abbott@abbott ED  
 REDACTED /lake/ppd/abbott@abbott;  
 REDACTED /lake/pprd/abbott@abbott; REDACTE D  
 REDACTED /lake/ppd/abbott@abbott; REDACTED  
 REDACTED /lake/ppd/abbott@abbott; REDACTED  
 REDACTED /lake/ppd/abbott@abbott; REDA  
 REDACTED lake/ppd/abbott@abbott; REDACT  
 REDACTED lake/ppd/abbott@abbott; RE )  
 REDACTED lake/ppd/abbott@abbott; D/REDACT  
 REDACTED /lake/ppd/abbott@abbott; REDACTE  
 REDACTED lake/ppd/abbott@abbott; REDACTED  
 REDACTED /lake/ppd/abbott@abbott; RE  
 REDACTED lake/ppd/abbott@abbott; REDACTED  
 REDACTED /lake/ppd/abbott@abbott; REDACTED  
 REDACTED lake/ppd/abbott@abbott; RED  
 REDACTED /lake/ppd/abbott@abbott; REDACTED  
 REDACTED lake/ppd/abbott@abbott; REDACTED  
 REDACTED /lake/ppd/abbott@abbott; REDACTED  
 REDACTED lake/ppd/abbott@abbott; REDACT  
 REDACTED /lake/ppd/abbott@abbott; ED REDACTED  
 REDACTED lake/ppd/abbott@abbott; REDACTE  
 REDACTED lake/ppd/abbott@abbott D

Subject: REP AWARENESS: Depakote Schizophrenia Trial  
 Date: Mon Aug 14 2006 18:17:43 EDT

REDACTED ED and REDACTED CTER, please forward this on to NSR and SAE sales management.

Representative Awareness Literature

The attached literature is being provided to you to keep you aware of professional and consumer literature recently appearing in the public domain. This communication is intended to keep you up to date with literature in the public domain having relevance to our business.

The information in this communication has not been reviewed to confirm the accuracy of its content. Neither does it mean that Abbott agrees with statements, positions, opinions, or conclusions in the publication. This literature may not be discussed with, distributed to, or shown to our customers, or used for the promotion of our products.

Talk to your manager if you have questions about the use of this information.

Results from Abbott study M02-547 (Title: A Randomized, Double-Blind Study of the Safety and Efficacy of Depakote® ER plus an Atypical Antipsychotic vs. an Atypical Antipsychotic Alone in the

Treatment of Schizophrenia) were posted on the clinicalstudyresults.org website on August 11, 2006.

The study was a Phase II, placebo-controlled, double-blind, randomized, parallel-group, multicenter study designed to assess the safety and efficacy of Depakote ER in combination with either olanzapine or risperidone vs. antipsychotic monotherapy with olanzapine or risperidone for the treatment of schizophrenia. In this study the combination of Depakote ER with olanzapine or risperidone did not result in statistically significant clinical efficacy benefits beyond those observed with antipsychotic monotherapy. Depakote ER in combination with atypical antipsychotic therapy was as well tolerated as therapy with risperidone or olanzapine alone.

Depakote ER and Depakote are not FDA approved as treatments for schizophrenia in any age group. Results from the current trial were not intended to support a regulatory submission for an indication for Depakote ER in schizophrenia.

Depakote ER is FDA approved as a treatment for acute manic and mixed episodes associated with bipolar disorder, with or without psychotic features, in adults aged 18 years and older.

Abbott is committed to disclosing all results in company-sponsored clinical trials and to advancing scientific understanding of its products. As such, results from this trial will also be submitted in manuscript form for publication consideration by an appropriate peer-reviewed journal.

Any inquiries or questions from healthcare providers regarding this trial should be directed to Medical Information.

REDACTED

REDACTED  
Marketing Director  
Abbott Neuroscience  
Neuroscience Marketing  
Abbott

REDACTED  
200 Abbott Park Road  
Abbott Park, IL 60064

Office REDACTED  
Fax REDACTED

REDACTED@abbott.com

This communication may contain information that is proprietary, confidential, or exempt from disclosure. If you are not the intended recipient, please note that any other dissemination, distribution, use or disclosure of this information is strictly prohibited. If you have received this communication in error, please notify the sender immediately by e-mail and delete this communication from your system. Do not disseminate, distribute, use or disclose this information to any other person. If you are the intended recipient, please do not change the distribution list. Thank you for your cooperation.